Patient P-02493
Synthetic patientMETA-24 · Day 169 · 25–34 · M · baseline S07Steering view · 3DOpen companion preview
Therapy response
Unstable
Tolerance
Favorable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Declining
Discontinuation risk
31%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 META-24 started — Baseline state S07
- Day 32 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 32.
Primary contributors, last 14 days
- Inflammatory activity+11
- Treatment adherence-7
- Nutritional resilience-5
- GI instability+4
- Toxicity+3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
Active minutes
Wearable43 min
worsening · -5.9 vs previous 14 d
Sleep duration
Wearable7 h
worsening · -0.5 vs previous 14 d
Energy level
Daily log4.4/10
worsening · -1.0 vs previous 14 d
Steps
Wearable3,826
worsening · -592 vs previous 14 d
GI burden
Companion29.4/100
worsening · +18.5 vs previous 14 d
Adherence
Companion78 %
stable · +2.7 vs previous 14 d
Sleep quality
Wearable48.4/100
worsening · -11.9 vs previous 14 d
Glucose, CGM daily mean
CGM133 mg/dL
worsening · +11.4 vs previous 14 d
This trajectory is decaying — what would help, what would not
Steering view →Heading towards failing · 53 from the failing basin, 46 from restoration.
Would help
- No untried action with strong evidence. Compose one from primitives.
- More proteinGI -4.2 next day on high-intake days · n 17
Would not help
- BR-03 Behavioural Recommendationonly 22% improved among 9 similar
- Keep histamine lowGI +3.4 next day on high-intake days · n 9
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Protein-4.2supporter · 95%
- Histamine load+3.4detractor · 95%
- Alcohol+1.9no signal · 48%
- Caffeine+1.4no signal · 37%
- Simple carbohydrates+0.2no signal · 15%
- Dietary fat load+0.1no signal · 15%
- Insoluble fibre+0.1no signal · 15%
- Ultra-processed food+0.1no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓30
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↓20
- Wearable3,826 steps/day
DNA
Fictional pharmacogenomic panel
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 78/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeHigh
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 43 ms
- Sleep
- 7.3 h
- Steps
- 4,128
- Resting HR
- 68 bpm
Daily log: GI score 29, nutritional resilience 58, adherence 78.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Eat slowly and stop at comfortable fullness — smaller volume, more often
What to do
- Log the daily check-in; one line is enough
- A 15-minute walk after lunch
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the dose at the same time relative to your evening meal
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-02552 | 46% | S07 | AD-05 | no change | 29 |
| P-02093 | 39% | S05 | AD-05 | no change | 40 |
| P-02285 | 34% | S14 | AD-05 | no change | 39 |
| P-02031 | 31% | S12 | AD-05 | improved | 47 |
| P-02564 | 51% | S15 | BR-03 | improved | 32 |
| P-02522 | 38% | S01 | BR-03 | no change | 40 |
| P-02308 | 37% | S13 | BR-03 | no change | 27 |
| P-02087 | 35% | S01 | BR-03 | no change | 40 |
| P-02325 | 35% | S19 | BR-03 | no change | 33 |
| P-02331 | 34% | S14 | BR-03 | improved | 34 |
| P-02439 | 33% | S08 | BR-03 | no change | 40 |
| P-02267 | 28% | S09 | BR-03 | no change | 45 |